$MYGN (+32.0% pre) Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates https://t.co/4O2l2Atmgs
$GENI | Genius Sports Q2'25 Earnings Highlights 🔹 Revenue: $118.7M (Est. $118.3M) 🟢; UP +24% YoY 🔹 EPS: ($0.21) (Est. -$0.01) 😕 🔹 Net Loss: ($53.9M); driven by one-time stock comp & NFL warrants
$GENI (+4.2% pre) Genius Sports Reports 24% Group Revenue Growth, Record Group Adj. EBITDA and Increased Full-Year 2025 Guidance https://t.co/J72PIOdv5J
Genius Sports reported second-quarter revenue of $118.7 million, exceeding analysts’ consensus of $118.3 million and marking a 24% increase from a year earlier. The sports-data provider posted a net loss of $53.9 million, or $0.21 a share, wider than Wall Street’s projected $0.01 loss, with the shortfall attributed largely to one-off stock-based compensation expenses and costs linked to NFL warrants. The company said adjusted earnings before interest, taxes, depreciation and amortisation reached a record, without providing a figure, and it raised its full-year 2025 outlook. Genius now expects roughly $645 million in revenue for the year, up from previous guidance and implying about 26% growth. The shares rose about 4% in pre-market trading following the announcement.